SARS-CoV-2 - Favipiravir - Therapeutic Candidates

SARS-CoV-2 - Favipiravir - Therapeutic Candidates


Favipiravir, also known as T-705 or Avigan, is a pyrazine-derived antiviral used against RNA viruses. This molecule is an inhibitor of the viral RNA-dependent RNA polymerase. Favipiravir is believed to act selectively on RNA polymerases of viruses and not on those of host cells and it has no action on DNA viruses.  Favipiravir would therefore have very few side effects except in pregnant women because it would have a potential for teratogenicity and embryotoxicity in humans. This is why it is currently only marketed in Japan and banned in Europe.
Favipiravir has shown good results against influenza viruses, especially oseltamivir-resistant viruses. A first study, carried out in China, showed that favipiravir could reduce the healing time of Covid-19 from 11 to 4 days for mildly affected patients. Other studies are underway to determine whether favipiravir may be a good candidate for the treatment of Covid-19 caused by CoV-2 SARS.

Search result : 108 product found

Refine your search :

RUOCE / IVD
  • Unconjugated 22
  • [3H] 1
  • Biochemicals 82
  • Inhibitor/Antagonist/Agonist 25
  • Radiochemicals 1
  • virus 3
  • Assay 3
APPLY FILTERS
REINITIALIZE


Cat#
Description
Cond.
Price Bef. VAT
orb146260-1g
 1g 
HY-14768-100mg
 100mg 
HY-14768-10mg
 10mg 
orb1227532-100mg
 100mg 
orb640745-25mg
 25mg 
orb1300424-50mg
 50mg 
orb1300424-10mg
 10mg 
orb1225488-100mg
 100mg 
orb1225488-2mg
 2mg 
orb1300424-5mg
 5mg 
orb640745-5mg
 5mg 
orb1225488-5mg
 5mg 
orb1225488-25mg
 25mg 
orb1225488-50mg
 50mg 
orb1225488-10mg
 10mg 
orb1300424-100mg
 100mg 
orb1300424-500mg
 500mg 
orb1738625-100mg
 100mg 
orb1738625-50mg
 50mg